Inducing chimeric antigen receptor (CAR) regulatory T cells in-vivo: A novel concept for a potential feasible cure of demyelinating diseases.

Chimeric antigen receptor (CAR) regulatory T cell (Treg) therapy has approved promising in murine experiments. It comprises from ex-vivo introduction of CARs to the Tregs of the recipient, and infusing them back thereafter. This process requires enormous amounts of equipment and expertise and therefore, cannot be considered feasible for people with demyelinating diseases, even if it proves to be effective and safe in the future. The presented novel concept introduces feasibility to CAR Treg therapy, by shifting most of the ex-vivo processes in-vivo. Inter-disciplinary discussions on such concepts is encouraged among experts in different fields.